Exchange: NASDAQ·Updated 04:15 PM EDT
ARVN logo

ARVN Arvinas Inc

$8.30
$0.01
(0.12%)
Today
Closed $8.30
$0.00
(0.00%)
After Hours
EarningsNov 4
Mkt Cap$542.05M
Vol638,417.00

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
47

Neutral Sentiment

How do you feel about ARVN?

Advertisement|Remove ads.